Tony Michael Argenbright

Array ( [id] => 12751114 [patent_doc_number] => 20180142205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => DEVICE AND USE THEREOF IN CELL EXPERIMENTS IN VITRO [patent_app_type] => utility [patent_app_number] => 15/540700 [patent_app_country] => US [patent_app_date] => 2015-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15540700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813717 [patent_doc_number] => 20160159878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'NOGO Receptor Antagonists' [patent_app_type] => utility [patent_app_number] => 14/952613 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 65116 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568625 [patent_doc_number] => 20170107268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'INSULIN RECEPTOR PARTIAL AGONISTS' [patent_app_type] => utility [patent_app_number] => 14/945461 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 38020 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14945461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689577 [patent_doc_number] => 20170355743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => INSULIN RECEPTOR PARTIAL AGONISTS [patent_app_type] => utility [patent_app_number] => 15/527363 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11642453 [patent_doc_number] => 09663810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-30 [patent_title] => 'Methods of cell culture' [patent_app_type] => utility [patent_app_number] => 14/941984 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 20802 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14941984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227693 [patent_doc_number] => 10501557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Mutated immunoglobulin-binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/526941 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9330 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15526941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704389 [patent_doc_number] => 10954309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Mutated immunoglobulin-binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/525688 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7900 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15525688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704389 [patent_doc_number] => 10954309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Mutated immunoglobulin-binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/525688 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7900 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15525688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704389 [patent_doc_number] => 10954309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Mutated immunoglobulin-binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/525688 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7900 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15525688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704389 [patent_doc_number] => 10954309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Mutated immunoglobulin-binding polypeptides [patent_app_type] => utility [patent_app_number] => 15/525688 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7900 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15525688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15132741 [patent_doc_number] => 10479817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-19 [patent_title] => Templates for controlling synthesis of nanoparticles into discrete assemblies [patent_app_type] => utility [patent_app_number] => 14/931805 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 16 [patent_no_of_words] => 4428 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10776234 [patent_doc_number] => 20160122391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'SHORT BETA-DEFENSIN-DERIVED PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/880238 [patent_app_country] => US [patent_app_date] => 2015-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 18546 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14880238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683918 [patent_doc_number] => 11779628 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases [patent_app_type] => utility [patent_app_number] => 15/516943 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 123 [patent_no_of_words] => 108072 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10712696 [patent_doc_number] => 20160058844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => '\"Bilirubin Excretion Enhancer\"' [patent_app_type] => utility [patent_app_number] => 14/877228 [patent_app_country] => US [patent_app_date] => 2015-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4390 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14877228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11023623 [patent_doc_number] => 20160220578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'Combination Therapy for Tuberculosis' [patent_app_type] => utility [patent_app_number] => 14/876311 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18521 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14876311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436421 [patent_doc_number] => 20170037442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'CASEIN HYDROLYSATE' [patent_app_type] => utility [patent_app_number] => 14/876413 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 5877 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14876413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963588 [patent_doc_number] => 20170267741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'TUMOR VASCULAR DISRUPTING AGENT POLYPEPTIDE, GENE, EXPRESSION VECTOR, AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/324669 [patent_app_country] => US [patent_app_date] => 2015-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2723 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15324669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670857 [patent_doc_number] => 20160017002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'Process for Preparing Eptifibatide' [patent_app_type] => utility [patent_app_number] => 14/842332 [patent_app_country] => US [patent_app_date] => 2015-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15282 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14842332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10450689 [patent_doc_number] => 20150335703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES' [patent_app_type] => utility [patent_app_number] => 14/819075 [patent_app_country] => US [patent_app_date] => 2015-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7898 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14819075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962100 [patent_doc_number] => 20170266253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'ANTITHETICAL REGULATION OF ENDOTHELIAL ACE AND ACE2 BY BRG1-FOXM1 COMPLEX UNDERLIES PATHOLOGICAL CARDIAC HYPERTROPHY' [patent_app_type] => utility [patent_app_number] => 15/500161 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 7650 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15500161 [rel_patent_id] =>[rel_patent_doc_number] =>)